文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

载米托坦脂质纳米粒的亲水性涂层:黏膜黏附的初步研究。

Hydrophilic coating of mitotane-loaded lipid nanoparticles: preliminary studies for mucosal adhesion.

机构信息

School of Chemical Engineering, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

出版信息

Pharm Dev Technol. 2013 May-Jun;18(3):577-81. doi: 10.3109/10837450.2011.614250. Epub 2011 Sep 29.


DOI:10.3109/10837450.2011.614250
PMID:21958059
Abstract

The aim of the present work was to load mitotane, an effective drug for adrenocortical carcinoma treatment, in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). The SLN and NLC were successfully prepared by high shear homogenization followed by hot high pressure homogenization. Formulations were composed of cetyl palmitate as the solid lipid for SLN, whereas for NLC PEGylated stearic acid was selected as solid lipid and medium chain triacylglycerols as the liquid lipid. Tween® 80 and Span® 85 were used as surfactants for all formulations. The particle size, zeta potential, polydispersity index (PI), encapsulation efficiency (EE), and loading capacity (LC) were evaluated. The SLN showed a mean particle size of 150 nm, PI of 0.20, and surface charge -10 mV, and the EE and LC could reach up to 92.26% and 0.92%, respectively. The NLC were obtained with a mean particle size of 250 nm, PI of 0.30, zeta potential -15 mV and 84.50% EE, and 0.84% LC, respectively. Hydrophilic coating of SLN with chitosan or benzalkonium chloride was effective in changing zeta potential from negative to positive values. The results suggest that mitotane was efficiently loaded in SLN and in NLC, being potential delivery systems for improving mitotane LC and controlled drug release.

摘要

本工作旨在将米托坦(一种治疗肾上腺皮质癌的有效药物)载入固体脂质纳米粒(SLN)和纳米结构脂质载体(NLC)中。通过高剪切匀化随后进行热高压匀化成功制备了 SLN 和 NLC。配方由十六烷棕榈酸酯组成,作为 SLN 的固体脂质,而对于 NLC,选择了聚乙二醇化硬脂酸作为固体脂质,中链三酰基甘油作为液体脂质。Tween®80 和 Span®85 被用作所有制剂的表面活性剂。评估了粒径、Zeta 电位、多分散指数(PI)、包封效率(EE)和载药量(LC)。SLN 的平均粒径为 150nm,PI 为 0.20,表面电荷为-10mV,EE 和 LC 可分别达到 92.26%和 0.92%。NLC 的平均粒径为 250nm,PI 为 0.30,Zeta 电位为-15mV,EE 为 84.50%,LC 为 0.84%。用壳聚糖或苯扎氯铵对 SLN 进行亲水性包被可有效将 Zeta 电位从负值变为正值。结果表明,米托坦可有效地载入 SLN 和 NLC 中,这两种载体均具有提高米托坦 LC 和控制药物释放的潜力。

相似文献

[1]
Hydrophilic coating of mitotane-loaded lipid nanoparticles: preliminary studies for mucosal adhesion.

Pharm Dev Technol. 2011-9-29

[2]
Optimizing SLN and NLC by 2(2) full factorial design: effect of homogenization technique.

Mater Sci Eng C Mater Biol Appl. 2012-4-20

[3]
Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.

Int J Pharm. 2012-8-4

[4]
Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications.

Int J Nanomedicine. 2012-4-11

[5]
Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).

Eur J Pharm Biopharm. 2008-10

[6]
Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery.

Nanotechnology. 2010-12-20

[7]
Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.

Int J Pharm. 2011-1-8

[8]
Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC.

Colloids Surf B Biointerfaces. 2010-7-27

[9]
Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers.

Chem Pharm Bull (Tokyo). 2010-5

[10]
Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.

Colloids Surf B Biointerfaces. 2011-5-26

引用本文的文献

[1]
Lipid Nanoparticles for the Posterior Eye Segment.

Pharmaceutics. 2021-12-31

[2]
Nasal delivery of nanotherapeutics for CNS diseases: challenges and opportunities.

Nanomedicine (Lond). 2021-12

[3]
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.

Eur J Drug Metab Pharmacokinet. 2021-9

[4]
An Updated Overview on Nanonutraceuticals: Focus on Nanoprebiotics and Nanoprobiotics.

Int J Mol Sci. 2020-3-26

[5]
Nanopharmaceutics: Part I-Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU.

Pharmaceutics. 2020-2-11

[6]
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I.

Pharmaceuticals (Basel). 2019-10-10

[7]
Association of Platelet-Rich Plasma and Auto-Crosslinked Hyaluronic Acid Microparticles: Approach for Orthopedic Application.

Polymers (Basel). 2019-9-26

[8]
Nanostructured lipid carriers: versatile oral delivery vehicle.

Future Sci OA. 2016-7-15

[9]
The Impact of Variables on Particle Size of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers; A Comparative Literature Review.

Adv Pharm Bull. 2016-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索